.jpg?format=webp&quality=80&width=3840)
The present investigation evaluated the effect of a 2‐year supplementation with a highly concentrated docosahexaenoic acid (DHA) product with antioxidant activity on nonproliferative diabetic retinopathy (NPDR). There were improvements in serum HbA1c levels in both groups, and the change to milder stages of the disease was greater in the DHA group, although not statistically significant. Although the protective role of nutraceutical supplementation with DHA in mild stages was less evident, the evidence is encouraging. Furthermore, it allows speculation about the protective role of DHA supplementation in non‐early stages of diabetic retinopathy, in which the most relevant biomarkers of inflammatory stress can act as a more effective therapeutic target for nutraceutical supplementation.
Like
Save
Share